eXoZymes (NASDAQ:EXOZ) Releases Quarterly Earnings Results

eXoZymes (NASDAQ:EXOZ) released its earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, FiscalAI reports.

eXoZymes Price Performance

EXOZ traded up $0.21 during trading on Monday, hitting $7.36. 5,497 shares of the stock traded hands, compared to its average volume of 3,364. The business has a 50 day moving average price of $9.11 and a 200 day moving average price of $11.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.53 and a quick ratio of 4.53. eXoZymes has a twelve month low of $7.08 and a twelve month high of $18.40. The company has a market cap of $61.82 million, a price-to-earnings ratio of -9.56 and a beta of 2.52.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of eXoZymes in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, eXoZymes currently has an average rating of “Sell”.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.